Abeona Therapeutics Inc vs Trade Desk Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Trade Desk Inc trades at $13.49 (market cap $6.29B). The key difference: Trade Desk Inc is far larger — about 14.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TTD | |
|---|---|---|
Market Cap | $424.33M | $6.29B |
Sector | Health | Technology |
52-Week High | $7.45 | $55.36 |
52-Week Low | $4.17 | $13.39 |
Enterprise Value | $279.23M | $5.24B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
The Trade Desk (TTD) is trading at $13.80, down 21.9% in 24 hours and near 7-year lows following disappointing Q2 earnings. Revenue grew just 3% to $715 million, missing guidance, while Q3 guidance projects a 12% decline. Technical indicators show bearish momentum with support at $13 and resistance at $15. Despite strong profitability metrics including 76.9% gross margins, recent execution gaps and advertiser pressure have triggered multiple analyst downgrades.
The outlook remains challenging with near-term revenue headwinds and competitive pressures. While valuation appears reasonable at 16.4x P/E, the stock faces significant execution risks and sentiment deterioration. Recovery depends on stabilizing advertiser relationships and reversing recent market share losses in the ad-tech sector.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →